Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PerkinElmer, a life science research and drug discovery company, has launched its specialized good manufacturing practice services for radiosynthesis of compounds for absorption, distribution, metabolism and excretion research studies.
Subscribe to our email newsletter
PerkinElmer said that its good manufacturing practice (GMP) radiosynthesis services provide advanced expertise for the manufacturing of radiolabeled compounds to help pharmaceutical, biotechnology and contract research organizations accelerate drug development outcomes.
The company’s GMP radiosynthesis services are reportedly designed to support the critical preclinical drug development efforts by assuring GMP compliance and quality of service to help research groups meet their aggressive deadlines with robust results. The service tags target drug candidates with radioactive materials to help research groups discover what happens to these compounds in the human body by measuring and monitoring the radioactivity.
According to the company, the GMP radiosynthesis services support team leverages more than five decades of radioactive materials expertise backed by GMP capabilities, including a new GMP radiosynthesis facility and a vast compound catalog for screening experimentation.
Richard Eglen, president of bio-discovery at PerkinElmer, said: “We are very pleased to announce the launch of PerkinElmer’s GMP radiosynthesis services to help our customers achieve better early drug development outcomes. Our GMP services team uniquely combines technical expertise in the manufacture of radiolabeled compounds with the industry knowledge required to meet our clients’ exacting regulatory and documentation requirements.”